Mike Rhee - Senti Biosciences General Secretary
| SNTI Stock | USD 0.85 0.01 1.38% |
Executive
Mike Rhee is General Secretary of Senti Biosciences
| Address | 2 Corporate Drive, South San Francisco, CA, United States, 94080 |
| Phone | 650 239 2030 |
| Web | https://www.sentibio.com |
Senti Biosciences Management Efficiency
The company has return on total asset (ROA) of (0.6777) % which means that it has lost $0.6777 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.9462) %, meaning that it created substantial loss on money invested by shareholders. Senti Biosciences' management efficiency ratios could be used to measure how well Senti Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.65. The current Return On Capital Employed is estimated to decrease to -0.87. As of now, Senti Biosciences' Net Tangible Assets are increasing as compared to previous years. The Senti Biosciences' current Non Currrent Assets Other is estimated to increase to about 4.4 M, while Total Assets are projected to decrease to under 106.2 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Natasha Esq | X4 Pharmaceuticals | N/A | |
| Geoffrey MD | Barinthus Biotherapeutics plc | 41 | |
| Andrew Smith | Medicus Pharma Ltd | 57 | |
| Viktoria Slepeniuk | Medicus Pharma Ltd | N/A | |
| James CPA | Medicus Pharma Ltd | 61 | |
| Kristina MBA | Aligos Therapeutics | N/A | |
| Viktoriia Slepeniuk | Medicus Pharma Ltd | N/A | |
| MPH MD | Karyopharm Therapeutics | N/A | |
| Eyal Talor | CEL SCI Corp | 70 | |
| Anna JD | Medicus Pharma Ltd | N/A | |
| Gemma Brown | Barinthus Biotherapeutics plc | 36 | |
| Lucinda Warren | Cue Biopharma | 56 | |
| Francesco MD | Genenta Science SpA | 58 | |
| Faisal MD | Medicus Pharma Ltd | 51 | |
| Adrienne Farid | Century Therapeutics | 63 | |
| KerriAnn CPA | Cue Biopharma | 55 | |
| Elizabeth MBA | Barinthus Biotherapeutics plc | N/A | |
| Brennan FACS | Medicus Pharma Ltd | 64 | |
| Brian Austad | Karyopharm Therapeutics | N/A | |
| Margaret MD | Barinthus Biotherapeutics plc | 67 | |
| Maryann Adesso | Medicus Pharma Ltd | N/A | |
Management Performance
| Return On Equity | -3.95 | ||||
| Return On Asset | -0.68 |
Senti Biosciences Leadership Team
Elected by the shareholders, the Senti Biosciences' board of directors comprises two types of representatives: Senti Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Senti. The board's role is to monitor Senti Biosciences' management team and ensure that shareholders' interests are well served. Senti Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Senti Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Faraz Siddiqui, Senior Operations | ||
| Thomas Chung, Vice Development | ||
| Susan Kahlert, Controller | ||
| Kanya MD, Head President | ||
| Yvonne MBA, Treasurer CFO | ||
| Wilson Wong, Scientific Board | ||
| Philip Lee, CoFounder CTO | ||
| Susan Berland, Senior Director | ||
| Mike Rhee, General Secretary | ||
| Jay Cross, Chief Officer | ||
| Dee Dragon, Senior Operations | ||
| James Collins, Chairperson CoFounder | ||
| Deborah Knobelman, CFO Treasurer | ||
| Robert JD, Senior Affairs |
Senti Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Senti Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -3.95 | ||||
| Return On Asset | -0.68 | ||||
| Current Valuation | 39.75 M | ||||
| Shares Outstanding | 26.29 M | ||||
| Shares Owned By Insiders | 56.73 % | ||||
| Shares Owned By Institutions | 22.48 % | ||||
| Number Of Shares Shorted | 752.59 K | ||||
| Price To Book | 2.69 X | ||||
| Price To Sales | 55.46 X | ||||
| Gross Profit | (37.6 M) |
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Senti Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. For more detail on how to invest in Senti Stock please use our How to Invest in Senti Biosciences guide.You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Is there potential for Biotechnology market expansion? Will Senti introduce new products? Factors like these will boost the valuation of Senti Biosciences. If investors know Senti will grow in the future, the company's valuation will be higher. Understanding fair value requires weighing current performance against future potential. All the valuation information about Senti Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.87) | Revenue Per Share | Quarterly Revenue Growth (1.00) | Return On Assets | Return On Equity |
The market value of Senti Biosciences is measured differently than its book value, which is the value of Senti that is recorded on the company's balance sheet. Investors also form their own opinion of Senti Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Senti Biosciences' true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Senti Biosciences' market value can be influenced by many factors that don't directly affect Senti Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Senti Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Senti Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Senti Biosciences' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.